Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients

N. R. Montanari, N. Conceição-Neto, I. Van Den Wyngaert, G. W. Van Oord, Z. M. A. Groothuismink, S. Van Tilburg, R. A. De Man, J. Aerssens, A. Boonstra*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
29 Downloads (Pure)

Abstract

Long-term viremia control in chronic HBV patients occurs either spontaneously in inactive carrier (IC) patients or therapy-induced by nucleos(t)ide analogues (NUC). To better understand the characteristics of viremia control, we evaluated gene expression in purified leukocyte subsets from IC versus NUC-treated patients, and evaluated the putative modulatory effects of hepatitis B surface antigen (HBsAg). We observed that gene expression in NUC-treated patients differed markedly from IC patients, especially in dendritic cells, monocytes, and CD8+ T cells, while serum HBsAg levels had little effect. Nevertheless, based on our findings it cannot be excluded that HBsAg may act locally in the infected liver or preferentially affects HBV-specific cells.

Original languageEnglish
Pages (from-to)1471-1476
Number of pages6
JournalJournal of Infectious Diseases
Volume225
Issue number8
DOIs
Publication statusPublished - 15 Apr 2022

Bibliographical note

Publisher Copyright:
© 2020 The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Fingerprint

Dive into the research topics of 'Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients'. Together they form a unique fingerprint.

Cite this